GalNAc-T13 CRISPR/Cas9 KO Plasmid (h): sc-407103
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- GalNAc-T13 CRISPR/Cas9 Knockout (KO) Plasmid (h) is a pool of plasmids, each encoding Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed for maximum knockout efficiency using sequences derived from the GeCKO v2 library
- gRNA sequences direct Cas9 to induce site-specific double-strand breaks (DSBs) in the GalNAc-T13 genomic locus, resulting in gene knockout through non-homologous end joining (NHEJ)
- The puromycin resistance and RFP genes are flanked by LoxP sites, enabling removal of selection markers via Cre recombinase (Cre Vector: sc-418923) after establishing stable knockout cell lines
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
GalNAc-T13 CRISPR/Cas9 KO Plasmid (h) | sc-407103 | 20 µg | $397.00 |
Overview
GALNT13 encodes polypeptide N-acetylgalactosaminyltransferase 13 (GalNAc-T13), a Golgi-resident initiating enzyme for mucin-type O-glycosylation that transfers GalNAc to serine/threonine residues on nascent secretory and membrane proteins. By shaping O-glycan patterns on receptors, adhesion molecules, and mucins, GalNAc-T13 can influence protein stability, trafficking, and ligand interactions that feed into signaling and cell–cell communication processes. Altered GALNT13 expression has been reported in multiple tumor contexts and is associated with changes in malignant cell behaviors such as invasion and metastatic potential, consistent with a role for O-glycosylation in remodeling the extracellular interface. This gene is therefore relevant to studies of glycoprotein biosynthesis, secretory pathway function, and glyco-regulated signaling networks in human cells.
GalNAc-T13 CRISPR/Cas9 KO Plasmid (h) is a pool of plasmids designed for targeted disruption of the GALNT13 gene in human cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the GALNT13 together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.
The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the GALNT13 open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish GalNAc-T13 protein expression.
This CRISPR knockout system enables efficient generation of GALNT13-deficient cell models for investigation of GalNAc-T13 signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.
Key Features
- sgRNAs targeting GALNT13 exon(s) critical for GalNAc-T13 function
- Co-expression of SpCas9 and sgRNA from a single plasmid for simplified delivery
- GFP reporter for identification of transfected cells
- Pool of plasmids targeting multiple GALNT13 genomic sites to improve knockout efficiency
- Compatible with delivery by transfection
Design Variants
CRISPRs +/- HDRs
- gRNAs encoded by GalNAc-T13 CRISPR/Cas9 KO Plasmid (h) and GalNAc-T13 CRISPR/Cas9 KO Plasmid (h2) target distinct sites within the GALNT13 locus. One or both targeting designs may be available. See Related Products for availability.
- HDR donor constructs encoded by GalNAc-T13 HDR Plasmid (h) and GalNAc-T13 HDR Plasmid (h2) contain a puromycin resistance cassette and an RFP reporter flanked by GALNT13 homology arms to support homology-directed repair at defined GALNT13 target sites corresponding to the CRISPR/Cas9 KO designs. HDR donor availability may vary. See Related Products for availability.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.